Dashboard
Manage Tickers

IMMX


   

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

immix-biopharma-to-present-an-abstract-on-its-therapy-nxc-201-at-the-ash-67th-annual-meeting-december-69-2025-in-orlando-florida
Immix Biopharma To Present An Abstract On ...
10/07/2025 20:10:39

Immix Biopharma, Inc. ("ImmixBio", "Company", "We" or "Us" or "IMMX"), the global leade...

immix-biopharma-surpasses-50-enrollment-in-nexicart-2-trial-for-car-t-nxc-201-in-relapsedrefractory-al-amyloidosis-advancing-toward-bla-submission
Immix Biopharma Surpasses 50% Enrollment I...
09/18/2025 17:32:55

– On track for first FDA Biologics License Application (BLA) approved cell therapy in orphan indication relapsed/refractory AL ...

hc-wainwright--co-maintains-buy-on-immix-biopharma-raises-price-target-to-8
HC Wainwright & Co. Maintains Buy on Immix...
09/12/2025 10:35:28

HC Wainwright & Co. analyst Robert Burns maintains Immix Biopharma (NASDAQ:IMMX) with a Buy and raises the price target ...

Core News & Articles
12 Health Care Stocks Moving In Monday's A...
09/08/2025 21:07:27

immix-biopharma-gains-strategic-investment-from-goose-capital-and-dr-nancy-t-chang-financial-terms-not-disclosed
Immix Biopharma Gains Strategic Investment...
09/08/2025 20:08:02

Immix Biopharma, Inc. ("Immix", "Company", "We" or "Us" or "IMMX"), a clinical-stage bi...

immix-biopharma-advances-nxc-201-cell-therapy-in-al-amyloidosis-and-other-serious-diseases-plans-to-out-license-osd-programs
Immix Biopharma Advances NXC-201 Cell Ther...
08/06/2025 16:32:21

– Dosing ongoing and planned in a handful of Other Serious Diseases (OSD) –– Company plans to partner-out Other Serious Disease...

immix-biopharma-accelerates-us-nexicart-2-clinical-trial-in-relapsedrefractory-al-amyloidosis-says-it-is-on-track-for-first-bla-approved-cell-therapy-in-unaddressed-orphan-indication
Immix Biopharma Accelerates U.S. NEXICART-...
07/07/2025 13:37:47

– National Footprint of NEXICART-2 Trial Sites Expanded ––  On track for first Biologics License Application (BLA) approved cel...

hc-wainwright--co-reiterates-buy-on-immix-biopharma-maintains-7-price-target
HC Wainwright & Co. Reiterates Buy on Immi...
06/04/2025 11:18:47

HC Wainwright & Co. analyst Robert Burns reiterates Immix Biopharma (NASDAQ:IMMX) with a Buy and maintains $7 price target.

immix-biopharma-files-for-offering-of-up-to-135m-shares-of-common-stock
Immix Biopharma Files For Offering Of Up T...
06/03/2025 19:12:48

-SEC Filing

immix-biopharma-reports-nexicart-2-phase-12-trial-results-at-2025-asco-meeting-primary-endpoint
Immix Biopharma Reports NEXICART-2 Phase 1...
06/03/2025 18:57:36

Immix Biopharma today presented results at ASCO from its U.S. multi-center NEXICART-2 Phase 1/2 clinical trial of NXC-201, meet...

Core News & Articles
12 Health Care Stocks Moving In Friday's I...
05/23/2025 17:06:46

immix-biopharma-says-14-us-sites-actively-enrolling-in-us-multi-site-study-nexicart-2-anticipate-completing-nexicart-2-clinical-trial-ahead-of-schedule
Immix Biopharma Says 14 U.S. Sites Activel...
05/23/2025 13:07:38

– Patient enrollment exceeding expectations –– 14 U.S. sites actively enrolling; 10 U.S. sites added since last update –– Antic...

Core News & Articles
12 Health Care Stocks Moving In Friday's P...
05/23/2025 12:08:30

Core News & Articles
Market-Moving News for May 23rd
05/23/2025 11:07:46

OKLO: 24% | Shares of OKLO and nuclear-linked stocks are trading higher amid report that President Trump to sign orders to boos...

Core News & Articles
Why Intuit Shares Are Trading Higher By Ov...
05/23/2025 09:09:44

Core News & Articles
12 Health Care Stocks Moving In Thursday's...
05/22/2025 21:05:56

immix-biopharma-publishes-and-presents-results-for-cell-therapy-nxc-201-abstract-7508-at-asco
Immix Biopharma Publishes And Presents Res...
05/22/2025 20:05:18

– NXC-201 demonstrated a complete response (CR) rate of 71% (5/7 patients) –– No relapses recorded to-date; no safety signals i...

immix-biopharmas-nxc-201-nexicart-2-clinical-trial-data-chosen-for-oral-presentation-at-asco-2025
Immix Biopharma's NXC-201 NEXICART-2 Clini...
04/23/2025 14:07:03

— Oral presentation Tuesday, June 3, 2025 in Chicago —LOS ANGELES, April 23, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (&#...

hc-wainwright--co-reiterates-buy-on-immix-biopharma-maintains-7-price-target
HC Wainwright & Co. Reiterates Buy on Immi...
02/10/2025 16:55:02

HC Wainwright & Co. analyst Robert Burns reiterates Immix Biopharma (NASDAQ:IMMX) with a Buy and maintains $7 price target.

immix-biopharma-receives-fda-regenerative-medicine-advanced-therapy-designation-for-nxc-201
Immix Biopharma Receives FDA Regenerative ...
02/10/2025 14:36:46

FDA RMAT designation follows positive proof-of-concept U.S. clinical data from the NXC-201 NEXICART-2 clinical trial in relapse...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION